A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program

Therapeutic Advances in Gastroenterology

Volumn 6, Issue 5, 2013, Pages 344-357

  Tong, Kenneth ^a   Nicandro, Jean Paul ^b   Shringarpure, Reshma ^b   Chuang, Emil ^b   Chang, Lin ^c  

^a Medical Affairs   (United States)

^b Prometheus Laboratories Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alosetron; complications of constipation; ischemic colitis; postmarketing; risk evaluation and mitigation strategy; risk management program; safety; severe diarrhea predominant irritable bowel syndrome

Indexed keywords

ALOSETRON;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOODY DIARRHEA; CONSTIPATION; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; ISCHEMIC COLITIS; MAJOR CLINICAL STUDY; MALE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RISK MANAGEMENT;

EID: 84883376111     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X13491798     Document Type: Article

References (46)

1. Begaud B. Moride Y. Tubert-Bitter P. Chaslerie A. Haramburu F. (1994) False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol 38: 401–404.
2. Brandt L. Boley S. (2000) AGA technical review on intestinal ischemia. Gastroenterology 118: 954–968.
3. Camilleri M. Chey W. Mayer E. Northcutt A. Heath A. Dukes G. et al. (2001) A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant IBS. Arch Intern Med 161: 1733-1740.
4. Camilleri M. Northcutt A. Kong S. Dukes G. McSorley D. Mangel A. (2000) Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355: 1035–1040.
5. Chang L. Chey W. Harris L. Olden K. Surawicz C. Schoenfeld P. (2006) Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 101: 1069–1079.
6. Chang L. Kahler K. Sarawate C. Quimbo R. Kralstein J. (2008) Assessment of potential risk factors associated with ischaemic colitis. Neurogastroenterol Motil 20: 36–42.
7. Chang L. Tong K. Ameen V. (2010) Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 105: 866–875.
8. Charles J. Pullicino P. Stoopack P. Shroff Y. (2005) Ischemic colitis associated with naratriptan and oral contraceptive use. Headache 45: 386–389.
9. Chey W. Chey W. Heath A. Dukes G. Carter E. Northcutt A. et al. (2004) Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 99: 2195–2203.
10. Cole J. Cook S. Sands B. Ajene A. Miller D. Walker A. (2004) Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 99: 486–491.
11. Deana D. Dean P. (1995) Reversible ischemic colitis in young women. Association with oral contraceptive use. Am J Surg Pathol 19: 454–462.
12. FDA (2002) Briefing Document for the Joint Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Subcommittee, Background Package, 23 April 2002. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. [Available at: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3848B1_02_FDA%20Lotronex.pdf; accessed 8 February 2013]
13. FDA (2005) Guidance for Industry: Development and Use of Risk Minimization Action Plans. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. [Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071616.pdf; accessed 8 February 2013]
14. FDA (2012) Postmarketing Reporting of Adverse Drug Experiences. Federal Regulation (FDA 21 CFR 314.80); revised 1 April 2012. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. [Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80; accessed 8 February 2013]
15. FDA (2013) Approved Risk Evaluation and Mitigation Strategies (REMS). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. [Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm; accessed 8 February 2013]
16. Fletcher A. (1991) Spontaneous adverse drug reaction reporting versus event monitoring: a comparison. J R Soc Med 84: 341–344.
17. Gandhi S. Hanson M. Vernava A. Kaminski D. Longo W. (1996) Ischemic colitis. Dis Colon Rectum 39: 88–100.
18. Goldman S. (1998) Limitations and strengths of spontaneous reports data. Clin Ther 20(Suppl. C): C40–C44.
19. Hass D. Kozuch P. Brandt L. (2007) Pharmacologically mediated colon ischemia. Am J Gastroenterol 102: 1765–1780.
20. Hervé S. Beaugerie L. Bouhnik Y. Savoye G. Colombel J. Dyard F. et al. (2009) Irritable bowel syndrome is more frequent in patients hospitalized for ischaemic colitis: results of a case-control study. Neurogastroenterol Motil 21: 1170-e102.
21. Knudsen J. Friedman B. Chen M. Goldwasser J. (1998) Ischemic colitis and sumatriptan use. Arch Intern Med 158: 1946–1948.
22. Krause R. Ameen V. Gordon S. West M. Heath A. Perschy T. et al. (2007) A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 102: 1709–1719.
23. Lembo A. Olden K. Ameen V. Gordon S. Heath A. Carter E. (2004) Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2: 675–682.
24. Lewis J. (2010) Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol 4: 13–29.
25. Locke G. III Pemberton J. Phillips S. (2000) AGA technical review on constipation. Gastroenterology 118: 1766–1778.
26. Longstreth G. Yao J. (2009) Epidemiology, clinical features, high-risk factors, and outcome of acute large bowel ischemia. Clin Gastroenterol Hepatol 7: 1075–1080.
27. Matsumoto T. Iida M. Kimura Y. Nanbu T. Fujishima M. (1994) Clinical features in young adult patients with ischaemic colitis. J Gastroenterol Hepatol 9: 572–575.
28. Miller D. Bennett L. Hollis K. Tennis P. Cook S. Andrews E. (2006) A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther 24: 869–878.
29. Nicandro J. Shin P. Chuang E. (2012) Evaluation of treatment continuation with alosetron by IBS-D severity criteria. Curr Med Res Opin 28: 449–456.
30. Preventza O. Lazarides K. Sawyer M. (2001) Ischemic colitis in young adults: a single-institution experience. J Gastrointest Surg 5: 388–392.
31. Prometheus Laboratories Inc. (2010) LOTRONEX® (alosetron hydrochloride) prescribing information. [Available at: https://www.lotronex.com/_docs/Lotronex_PI.pdf; last updated September 2010; accessed 8 February 2013]
32. Radaelli F. Feltri M. Meucci G. Spinzi G. Terruzzi V. Minoli G. (2005) Ischemic colitis associated with rofecoxib. Dig Liver Dis 37: 372–376.
33. Sartoretti C. Sartoretti S. DeLorenzi D. Buchmann P. (1996) Intestinal non-rotation and pseudo obstruction in myotonic dystrophy: case report and review of the literature. Int J Colorectal Dis 11: 10–14.
34. Schwartz D. Smith D. (2004) Colonic ischemia associated with naratriptan use. J Clin Gastroenterol 38: 790–792.
35. Shafer R. Prentiss R. Bond J. (1984) Gastrointestinal transit in thyroid disease. Gastroenterology 86: 852–855.
36. Singh G. Mithal A. Triadafilopoulos G. (2004) Patients with irritable bowel syndrome have a high-risk of developing ischemic colitis [abstract no. 349]. Gastroenterology 126(4 Suppl. 2): A41.
37. Sotiriadis J. Brandt L. Behin D. Southern W. (2007) Ischemic colitis has a worse prognosis when isolated to the right side of the colon. Am J Gastroenterol 102: 2247–2252.
38. Suh D. Kahler K. Choi I. Shin H. Kralstein J. Shetzline M. (2007) Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis. Aliment Pharmacol Ther 25: 681–692.
39. Tennis P. Andrews E. Hickman P. Miller D. Hollis K. Cook S. (2007) The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther 25: 317–322.
40. Thiéfin G. Beaugerie L. (2005) Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 72: 286–294.
41. van Dijk K. de Vries C. van den Berg P. Dijkema A. Brouwers J. de Jong-van den Berg L. (1998) Constipation as an adverse effect of drug use in nursing home patients: an overestimate. Br J Clin Pharmacol 46: 225–261.
42. Vinik A. Maser R. Mitchell B. Freeman R. (2003) Diabetic autonomic neuropathy. Diabetes Care 26: 1553–1579.
43. Walker A. Bohn R. Cali C. Cook S. Ajene A. Sands B. (2004) Risk factors for colon ischemia. Am J Gastroenterol 99: 1333–1337.
44. Weber J. (1984) Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs. In: Ed. Rainsford K. Velo G. (eds), Advances in Inflammation Research. Raven Press: New York.
45. Weiss-Smith S. Deshpande G. Chung S. Gogolak V. (2011) The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med 171: 591–593.
46. Zervoudis S. Grammatopoulos T. Iatrakis G. Katsoras G. Tsionis C. Diakakis I. et al. (2008) Ischemic colitis in postmenopausal women taking hormone replacement therapy. Gynecol Endocrinol 24: 257–260.